Skip to main content
. Author manuscript; available in PMC: 2017 Aug 2.
Published in final edited form as: JAMA. 2016 Aug 2;316(5):500–508. doi: 10.1001/jama.2016.10260

Figure 3. Prespecified Subgroup Analysis of Patients Who Died or Experienced Rehospitalization for Heart Failure by Type 2 Diabetes Status.

Figure 3

HR indicates hazard ratio. The median duration of follow-up was 179 days (interquartile range, 157–182 days) in the liraglutide group and 178 days (interquartile range, 150–183 days) in the placebo group.